Stevenage, United Kingdom

Pamela Joan Thomas

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Pamela Joan Thomas

Introduction

Pamela Joan Thomas is a notable inventor based in Stevenage, GB. She has made significant contributions to the field of biomedical research, particularly in the development of therapeutic solutions for diseases associated with beta-amyloid levels.

Latest Patents

Pamela holds a patent for "Humanized anti-beta-amyloid antibodies." This invention includes antigen binding proteins that specifically target beta-amyloid peptides, especially the human variant. The patent outlines methods for treating diseases characterized by elevated beta-amyloid levels, including Alzheimer's disease and conditions affecting the eye or optic nerve, such as age-related macular degeneration and glaucoma. The patent also covers pharmaceutical compositions that incorporate these antigen binding proteins and methods of their manufacture.

Career Highlights

Throughout her career, Pamela has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. Her work has focused on innovative solutions to combat diseases that significantly impact quality of life.

Collaborations

Pamela has collaborated with esteemed colleagues in her field, including Philippe Marc Louis Alard and Ian Richard Catchpole. These partnerships have contributed to the advancement of her research and the successful development of her patented technologies.

Conclusion

Pamela Joan Thomas is a pioneering inventor whose work in developing anti-beta-amyloid antibodies has the potential to transform treatment options for various diseases. Her contributions to biomedical research highlight the importance of innovation in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…